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Background: Fever and neutropenia (FN) is a common complication of pediatric cancer treatment, but hospital
utilization patterns for this condition are not well described.
Methods: Data were analyzed from the Kids’ Inpatient Database (KID), an all-payer US hospital database, for 2009.
Pediatric FN patients were identified using: age ≤19 years, urgent or emergent admit type, non-transferred, and a
combination of ICD-9-CM codes for fever and neutropenia. Sampling weights were used to permit national inferences.
Results: Pediatric cancer patients accounted for 1.5 % of pediatric hospital discharges in 2009 (n = 110,967), with 10.1 %
of cancer-related discharges meeting FN criteria (n = 11,261). Two-fifths of FN discharges had a “short length of stay”
(SLOS) of ≤3 days, which accounted for approximately $65.5 million in hospital charges. Upper respiratory infection
(6.0 %) and acute otitis media (AOM) (3.7 %) were the most common infections associated with SLOS. Factors
significantly associated with SLOS included living in the Midwest region (OR = 1.65, 1.22–2.24) or West region
(OR 1.54, 1.11–2.14) versus Northeast, having a diagnosis of AOM (OR = 1.39, 1.03–1.87) or viral infection (OR = 1.63,
1.18–2.25) versus those without those comorbidities, and having a soft tissue sarcoma (OR = 1.47, 1.05–2.04), Hodgkin
lymphoma (OR = 2.33, 1.62–3.35), or an ovarian/testicular tumor (OR = 1.76, 1.05–2.95) compared with patients without
these diagnoses.
Conclusion: FN represents a common precipitant for hospitalizations among pediatric cancer patients. SLOS admissions
are rarely associated with serious infections, but contribute substantially to the burden of hospitalization for pediatric FN.
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Fever and neutropenia (FN) is a common complication
of chemotherapy for pediatric cancer patients [1]. FN is
a well-recognized risk factor for morbidity and mortality
in pediatric cancer populations [2], and the current
standard of care is emergent broad-spectrum intravenous
antibiotics and inpatient hospitalization until phagocyte
recovery occurs [3, 4].
Despite the fact that hospitalizations for FN are
common among pediatric cancer patients, recent data are
limited regarding hospitalizations for pediatric FN at the
national level. A recent analysis from 115 participating* Correspondence: elmuelle@iupui.edu
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unless otherwise stated.institutions in the United States (US) identified about
12,000 admissions for FN among pediatric cancer patients
from 1995–2002, with a median length of stay (LOS) of
5 days [5]. No aggregate evaluation of hospitalizations for
FN in pediatric cancer patients across the US has been
published. A more comprehensive understanding of those
patients with a short LOS may help inform future research
aimed at decreasing the need for hospitalization of
pediatric FN patients at low risk for serious complications.
The purpose of this study was to characterize discharges
for pediatric cancer patients admitted non-electively and
discharged with a diagnosis of fever and neutropenia,
across the United States. We hypothesized that a substan-
tial portion of pediatric cancer admissions for FN will have
a short LOS, with few of these patients experiencing
serious infections. Understanding this group of patient
encounters could lead to interventions aimed at out-
patient rather than inpatient management.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study design and setting
Pediatric cancer patients admitted for FN were identified
from a cross-sectional analysis of pediatric discharges in
2009, using the Healthcare Cost and Utilization Project’s
(HCUP) Kids’ Inpatient Database (KID), compiled by the
Agency for Healthcare Research and Quality (AHRQ)
[6]. The KID is a nationally representative database that
samples 80 % of pediatric discharges and 10 % of uncom-
plicated births at both teaching and non-teaching hospi-
tals, compiled every third year since 1997; the most recent
year of data available at the time of this project was 2009.
The KID is designed to increase the statistical power to
detect and evaluate rare conditions among hospitalized
children. The KID has been used in multiple instances to
examine hospitalization patterns of care among children
in the US [7–13]. Data elements within the KID include
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes, LOS, patient
demographic characteristics, and hospital charges per
episode of care.
Discharge weights based on the KID sampling scheme
were applied to the data by AHRQ, to permit inferences
regarding national patterns of hospital utilization by the
authors. AHRQ provides information on the sampling
design variables. HOSPID, KID_STRATUM and DISCWT
are the cluster, the stratum, and the sample weight vari-
ables, respectively. We used survey estimation commands
(SVY commands) in STATA incorporating the sample
design variables. All data are presented as weighted values,
unless otherwise specified. The 2009 KID data contained
over 2 million unweighted discharges that represented
over 7 million discharges in the population that year. Our
analysis was based on de-identified national data and
therefore was considered exempt from human subjects
review by the University of Michigan Medical Institutional
Review Board.
Identification of cases
Using the KID, hospitalizations for pediatric cancer
patients were determined using the HCUP Clinical
Classification Software (CCS) for ICD-9-CM. The CCS
is a diagnosis and procedure categorization scheme
that aggregates ICD-9-CM codes into a smaller number of
clinically meaningful categories. CCS codes 11–45 encom-
pass all types of malignancies and therefore were used to
define the pediatric cancer subpopulation. Transfers were
excluded from all analyses for two reasons: (a) to avoid
duplicate encounters for the same episode of care since
patient identifiers are not included in this dataset; and
(b) to accurately assess LOS, which would have been
artificially shortened in the data of the transferring and
receiving hospitals. We ascertained the proportion of
children with FN who died while hospitalized; theywere included in our analyses as a clinically important
subgroup whose LOS was not affected by transfer.
Outcome and explanatory variables
One of the aims of our study was to identify febrile
neutropenic patient discharges associated with a relatively
short, uneventful inpatient course and to assess variables
associated with these discharges. Discharges with a short
LOS would be potential candidates for future outpatient
management strategies. Patients who develop fever while
inpatient are traditionally considered high risk and would
not qualify for early discharge or outpatient management
strategies [14]. Therefore, to define a discharge encounter
for “fever and neutropenia” (FN), the following criteria
were applied: age ≤19 years, admit type either urgent or
emergent (i.e., excluded elective admissions), and combin-
ation of ICD-9-CM discharge diagnosis of fever (780.6,
780.60, 780.61) and “neutropenia” (neutropenia [288.0],
pancytopenia [284.1], or decreased white blood cell count
[112.5]) in any of the discharge diagnosis fields (Fig. 1).
To identify co-occurring infections in patients with FN,
ICD-9-CM codes were utilized. For common diagnoses to
which multiple ICD-9-CM codes could map, general cat-
egories were defined, including pneumonia (480.x−485.x)
and upper respiratory infection (460.x−465.x). Bloodstream
infections were identified by the following ICD-9-CM
codes: bacteremia (790.7), septicemia (38.x), infection due
to a vascular device, implant or graft (996.62), or infection
due to central venous line (999.31, 999.32).
Our primary outcome of interest was the frequency of
discharges with a short LOS (SLOS), defined as ≤3 days
in order to capture all hospitalizations that would have
lasted 48 h or less. This threshold was selected because
of the clinical relevance of negative blood cultures at
48 h [15], and because LOS is counted based on the
number of midnights spent in the hospital [16]. For ex-
ample, a child admitted at 11:59 pm on the 1st of a
month who had negative blood cultures at 11:59 pm on
the 3rd day of the month could be discharged on the 4th
day of the month (LOS = 3 days).
Secondary outcomes for FN discharges were related to
population-adjusted frequency of discharges, mean LOS,
and mean and total hospital charges per discharge for FN.
Data Analyses
Descriptive statistics were used to demonstrate the distri-
bution of FN discharges by gender, age, race/ethnicity, and
primary payer type, hospital teaching and location status,
and hospital Census region. The frequency of discharges
for FN in pediatric oncology patients was described as the
rate of discharges per 100,000 US children per year, using
national Census data for 2009 [17]. Hospital charges were
adjusted from 2009 US$ to 2014 US$ using the Consumer
Price Index [18].
Fig. 1 Case selection strategy for “Fever and Neutropenia” – Kids’ Inpatient Database for 2009
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used to estimate factors associated with SLOS for
pediatric cancer patient encounters for FN; statistical
weights also accounted for clustering of patients by hos-
pital. Potential explanatory variables were selected for
the model a priori based on hypothesized clinical rele-
vance, which included: patient’s age, gender, primary ex-
pected payer, median household income for the patient’s
zip code, hospital location and teaching status, hospital
Census region, dichotomous variables for the presence
or absence of each of the top 10 most common cancer
diagnoses [19], and a dichotomous variables for types of
infections. We hypothesized that sociodemographic and
hospital level factors may influence admission and/or
discharge decision making based on resources of the
individual and within the community. Statistical analyses
were performed using STATA version 13.0 (Stata Corp,
College Station, TX).
Results
Characteristics of the study population
In 2009, there were a total of 7,370,203 weighted pediatric
discharges in the U.S. Among those, 1.5 % (n = 110,967)
were associated with a diagnosis of cancer. According to
the HCUP classification, 49 % (n = 54,868) of pediatric
cancer patients were admitted non-electively (coded as
either urgent or emergent). Of all discharges for
pediatric cancer patients, 10.1 % (n = 11,261) met criteria
for FN; among non-elective pediatric cancer discharges,
19.3 % met criteria for FN. Only 1.2 % of pediatric cancer
patient discharges ended in death—totaling 0.4 % among
the pediatric FN discharges.
Characteristics of pediatric cancer patient discharges
that met criteria for FN are presented in Table 1. The age
distribution for FN discharges demonstrated the majority
of patients are 0–9 years old, higher than the proportionamong overall pediatric cancer admission for patients 0–9
years old. In addition, the study population was found to
be predominately male and of non-Hispanic white race.
Most FN patients were insured, with private insurance
more common than public coverage. Just over one-half of
the FN discharges had an associated diagnosis of acute
lymphoblastic leukemia (ALL), versus 25 % of the overall
pediatric cancer discharges with a diagnosis of ALL.
In 2009, population-adjusted discharges for FN among
pediatric cancer patients occurred at a rate of 13.4 per
100,000 US children. Over the study period, FN dis-
charges in pediatric cancer patients represented 79,870
total inpatient days.
Discharge characteristics for pediatric FN discharges
The distribution of LOS for FN discharges is included in
Table 2, with SLOS admissions accounting for 41 % of all
FN discharges. For patients with SLOS, the most com-
monly associated infection was an upper respiratory infec-
tion, followed by acute otitis media (Table 2). Bloodstream
infection was present in 3.1 % of patients with SLOS, as
compared to 20.8 % whose LOS lasted 8–14 days.
Charges for pediatric FN discharges
The overall mean hospital charge for a pediatric cancer
patient discharge for FN was $52,160 (Table 3). As
expected, mean charges varied substantially by LOS cat-
egory. Given approximately 4,500 SLOS discharges for
pediatric FN at the national level in a year, FN discharges
with SLOS accounted for approximately $65.5 million in
hospital charges.
Factors associated with short LOS for pediatric FN discharges
In a multivariate analysis (Table 4), factors associated with
significantly increased odds of SLOS for FN included liv-
ing in the Midwest region (OR = 1.65, 1.22–2.24) or the
Table 1 Characteristics of discharges for non-transferred
pediatric cancer patients: overall and for fever and neutropenia
(FN) discharges – United States, 2009
Proportion of
overall pediatric
cancer discharges
Proportion of
pediatric FN
discharges
% (95 % CI)
Patient characteristics
Gender
Female 45.0 (44.2–45.8) 46.5 (45.0–48.0)
Age
0–4 years 28.9 (27.8–30.0) 36.7 (34.6–38.8)
5–9 years 22.0 (21.2–22.7) 27.9 (26.6–29.3)
10–14 years 21.3 (20.6–22.0) 18.2 (17.0–19.5)
15–19 years 27.8 (26.6–29.1) 17.2 (15.8–18.7)
Race/Ethnicity
White 48.4 (44.2–52.7) 55.7 (50.5–60.9)
Black 9.7 (8.4–11.2) 7.1 (5.7–8.7)
Hispanic 21.2 (17.7–25.3) 17.1 (13.6–21.3)
Asian/pacific islander 7.9 (6.7–9.4) 7.6 (6.0–9.4)
Primary payer
Public 39.2 (36.7–41.9) 37.1 (34.3–40.1)
Private 53.4 (50.9–55.9) 57.3 (54.1–60.4)
Self–pay 2.2 (1.5–3.1) 2.4 (1.4–3.9)
Other 5.2 (3.9–6.9) 3.2 (2.5–4.2)
Median household income per ZIP code
1st quartile 24.8 (22.5–27.3) 24.0 (20.7–27.8)
2nd quartile 25.3 (50.9–55.9) 25.1 (23.0–27.2)
3rd quartile 25.3 (1.5–3.1) 24.3 (22.2–26.6)
4th quartile 24.6 (21.8–27.6) 26.5 (22.6–30.9)
Type of cancer
ALL 24.6 (23.5–25.8) 44.3 (41.6–47.0)
Bone cancer 12.8 (12.0–13.6) 10.4 (9.1–12.0)
Central Nervous System tumor 9.6 (8.8–10.4) 6.2 (5.1–7.5)
AML 5.9 (5.5–6.3) 7.4 (5.9–9.1)
Soft tissue sarcoma 5.1 (4.7–5.6) 4.6 (3.9–5.4)
Neuroblastoma 4.5 (3.9–5.1) 4.7 (3.7–6.0)
Hodgkin lymphoma 3.2 (2.9–3.5) 2.9 (2.5–3.4)
Wilms tumor 2.7 (2.5–3.0) 3.0 (2.5–3.6)
Non–Hodgkin lymphoma 2.6 (2.3–2.9) 3.6 (3.1–4.3)
Ovarian or testicular tumor 1.7 (1.5–1.9) 0.7 (0.5–1.0)
Hospital characteristics
Hospital Location-Teaching Status
Rural 1.7 (1.0–2.8) 1.6 (0.7–3.3)
Urban, non-teaching 9.9 (7.0–13.8) 7.2 (4.4–11.5)
Urban, teaching 88.4 (84.4–91.5) 91.2 (86.7–94.3)
Table 1 Characteristics of discharges for non-transferred
pediatric cancer patients: overall and for fever and neutropenia
(FN) discharges – United States, 2009 (Continued)
Hospital region
Northeast 16.3 (11.2–23.0) 20.7 (13.6–30.2)
Midwest 21.5 (15.7–28.8) 26.0 (18.0–36.0)
South 36.3 (28.6–44.8) 40.2 (29.6–51.8)
West 25.9 (18.8–34.4) 13.1 (7.4–22.2)
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with the Northeast region. In addition, having a concomi-
tant diagnosis of acute otitis media (OR=1.39, 1.03–1.87)
or viral infection (OR=1.63, 1.18–2.25) was associated
with SLOS, compared with patients without those diagno-
ses. In terms of oncologic diagnoses, soft tissue sarcoma
(OR=1.25, 1.13–1.37), Hodgkin lymphoma (OR=1.66,
1.45–1.91), or ovarian/testicular tumors (OR=1.76, 1.05–
2.95) were also associated with SLOS, compared with
patients without these diagnoses.
Discussion
This study provides a recent, nationally representative
analysis of inpatient hospital discharges for FN among
pediatric cancer patients in the United States. Overall,
among non-elective discharges that were neither trans-
ferred nor ended in patient death, we found that about 1
of every 5 pediatric cancer-related hospital discharges is
related to FN. Of these, 41 % had a short LOS, which
accounted for over $66 million in hospital charges in 2009
(expressed in 2014 US$). Patients with soft tissue sarcoma,
Hodgkin lymphoma or ovarian/testicular tumors and
those with a diagnosis of acute otitis media or viral infec-
tion had increased odds of having short LOS comparedTable 2 Comparison of proportion of infectious diagnoses by
LOS category among pediatric cancer FN discharges
Overall LOS category
“Short
LOS”
4-7
days
8-14
days
15-30
days
31+
days
≤3 days
Proportion (%)
Proportion of FN DCs 41 33 16 7 3
No infection identified 75.9 82.7 77.3 66.9 62.7 44.4
Type of infection
Upper respiratory
infection
5.4 6.0 5.6 4.0 4.3 5.3
Acute otitis media 2.9 3.7 2.3 2.3 2.2 3.3
Bloodstream infection 10.4 3.1 9.5 20.8 23.9 35.6
Viral infection 2.3 3.1 2.3 1.6 0.2 0
Urinary tract infection 1.9 1.1 2.4 2.2 2.5 4.6
Pneumonia 1.2 0.3 0.6 2.3 4.1 6.8
Table 3 Mean charges for pediatric cancer fever and
neutropenia discharges: overall and by length of stay category -
United States, 2009
Mean charges Total charges
Overall $52,160 $587,398,210
Length of stay category
≤3 days – “Short LOS” $14,549 $67,296,971
4–7 days $33,423 $125,499,734
8–14 days $72,552 $128,683,775
15–30 days $166,316 $128,267,528
>30 days $412,730 $138,805,796
Charges are adjusted to 2014 dollars using the Consumer Price
Index adjustment
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mitigate healthcare expenditures and improve quality of
life for patients and their families through alternative man-
agement of pediatric FN in some cases.
The distribution of patient demographics found among
all pediatric cancer patients in this study is consistent with
the patterns observed in the SEER data regarding the same
patient population [20]. When comparing the age distribu-
tion of FN patient encounters to the overall pediatric cancer
population from our dataset, there are disproportionately
more patients in the 0–9 years age group. Some factors
contributing to younger patients suffering more FN events
could be specific malignancy diagnoses and the associated
intensity or duration of required treatment, type of central
line catheter (Broviac catheter versus Port-a-Cath) [21], and
exposures to infectious etiologies, particularly viruses [22].
This age-specific phenomenon merits further examination
with more detailed patient-level data, to investigate factors
related to increased risk for admission for FN.
Pediatric cancer patients represent a unique population
of medically complex patients whose use of the health care
system has not previously been well documented. For
those who met criteria for FN, a substantial portion of pa-
tient encounters (41 %) had SLOS (≤3 days) with a small
proportion of major infections documented. We believe
that SLOS encounters indicate a potentially modifiable
treatment process. There have been several studies sur-
rounding the cost of inpatient versus outpatient care for
FN, including a decision-analytic model for treatment
options for pediatric FN which indicated that the most
cost-effective therapy strategy was home-based parenteral
therapy [23]. The present study represents the first analysis
of the financial impact of hospitalization for pediatric
FN in the US healthcare system at the national level,
which demonstrates a large financial burden. In the
current healthcare reform environment, it will be essential
for future investigation of pediatric FN management to in-
clude comparisons of effectiveness and cost efficiencies re-
lated to alternative clinical management options. Analyseswill need to be undertaken that include the perspectives of
the healthcare system, pediatric oncology providers, and
the patients and families who are all potentially affected by
modifications in clinical management.
For pediatric FN patients with SLOS, the question re-
mains if a risk stratification system or admission followed
by step-down therapy approach, such as the ones imple-
mented for adult patients with FN [24, 25], would decrease
the number of patients requiring inpatient admission for
FN. The feasibility, efficacy and/or safety of alternative ther-
apies for FN in the pediatric population have been explored
by other investigators. A recent systematic review and
meta-analysis of 14 randomized, controlled trials of in-
patient versus outpatient, and oral versus parenteral,
management of pediatric low-risk FN showed no differ-
ences in efficacy or safety [26]. However, the authors
recognized the limitations of the review to include that
outcome measurements were not uniform among the
studies included and therefore their analysis may not
be generalizable. Despite initial attempts to risk stratify
pediatric cancer patients [27], no consensus on risk strati-
fication has been achieved [28], therefore hospitalization
for all FN patients’ remains common practice.
While primary insurance and median household income
per ZIP code were not found to be statistically significant
factors, it is appreciated that they play an important role
in the interaction of patients with the health care system.
It is possible that differences in resource availability for
certain families may influence their pre-hospital care and
during-hospital circumstances. Alternate approaches by
the hospital system or insurance plans could be imple-
mented to offset the financial burdens for these patients;
such as reimbursement for lodging near the hospital,
travel, and meals which could be less costly than an in-
patient admission. Patient and parent perspectives will be
important to assess and address when implementing new
strategies for the management of FN.
Another consideration is differences in findings across
US Census regions, which raise questions about modifica-
tions of care that may be more applicable to some regions
than others. Factors such as ease of access and distance to
patients’ cancer treatment centers, ability of local emer-
gency departments to provide adequate care for pediatric
cancer patients, and other system-wide practices, policies,
and coordination at the state and regional levels could
greatly affect the logistics of altering current standard
practices.
Pediatric cancer patients with FN are routinely admitted
to empirically treat and evaluate for a serious bacterial
infection. Our investigation revealed that the rate of
bloodstream infections among all pediatric cancer patient
encounters with FN was 10.4 %. This was consistent
with the lower limit of previous analyses that revealed
bacteremia rates among children with cancer to be
Table 4 Multivariate logistic regression to evaluate factors
associated with a “Short LOS” (≤3 days) among pediatric cancer
fever and neutropenia discharges
Factors Adjusted odds
ratio (OR)
95% CI P-value
Gender
Female 1.06 1.02–1.10 0.006
Age
15–19 years Ref
10–14 years 1.06 0.99–1.13 0.076
5–9 years 1.20 1.11–1.30 <0.001
0–4 years 1.08 1.01–1.15 0.029
Primary payer
Public Ref
Private 1.08 1.02–1.13 0.004
Self-pay 1.05 0.89–1.23 0.591
Other 0.96 0.85–1.08 0.467
Median household income per ZIP code
1st quartile Ref
2nd quartile 1.08 1.01–1.16 0.032
3rd quartile 1.10 1.03–1.18 0.01
4th quartile 1.07 1.00–1.15 0.05
Hospital location-teaching status
Urban, teaching Ref
Urban, non-teaching 1.12 0.96–1.31 0.16
Rural 2.01 1.57–2.58 <0.001
Hospital region
Northeast Ref
Midwest 1.22 1.09–1.36 <0.001
South 1.04 0.94–1.15 0.41
West 0.94 0.85–1.05 0.298
Type of infection
Upper respiratory infection 1.07 0.97–1.18 0.165
Acute otitis media 1.26 1.10–1.44 0.001
Bloodstream infection 0.21 0.18–0.24 <0.001
Viral infection 1.82 1.55–2.15 <0.001
Urinary tract infection 0.44 0.39–0.50 <0.001
Pneumonia 0.27 0.22–0.32 <0.001
Type of cancer
ALL 0.84 0.78–0.89 <0.001
Bone cancer 0.77 0.71–0.85 <0.001
Central nervous system tumor 0.99 0.92–1.07 0.787
AML 0.40 0.36–0.45 <0.001
Soft tissue sarcoma 1.25 1.13–1.37 <0.001
Neuroblastoma 0.56 0.48–0.66 <0.001
Hodgkin lymphoma 1.66 1.45–1.91 <0.001
Table 4 Multivariate logistic regression to evaluate factors
associated with a “Short LOS” (≤3 days) among pediatric cancer
fever and neutropenia discharges (Continued)
Wilms tumor 0.59 0.52–0.68 <0.001
Non-Hodgkin lymphoma 0.46 0.39–0.54 <0.001
Ovarian or testicular tumor 0.63 0.52–0.76 <0.001
Controlled for Race; CI = Confidence Interval, ALL = Acute Lymphoblastic
Leukemia; AML = Acute Myelogenous Leukemia; Type of Infection and Type of
Cancer are presented as dichotomous variables
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tion of bloodstream infections was higher for those pa-
tients with longer LOS, likely representing a higher
severity of illness among those with long LOS. Con-
versely, the proportion of SLOS discharges with a blood-
stream infection was lower, at 3.1 %. A future analysis with
patient-level data would better characterize whether pa-
tients with SLOS have reasons other than empiric antibi-
otics and monitoring that are necessitating hospitalization.
Interestingly, a recent analysis found the time to positive
blood cultures in febrile neonates was <24 h in over 90 %
of cases [32]. A similar analysis among pediatric cancer
patients could aid in decision-making for early discharge
with less inpatient observation time required.
Limitations
As an analysis of national administrative data, our
study has many strengths but also notable limitations.
Administrative data must rely on accuracy of ICD-9-CM
codes to identify the population of interest, which are sub-
ject to errors of omission or commission. We did not have
information regarding the cause for admission and there-
fore inferred the reason based on discharge diagnoses. FN
is not a single diagnostic code and was indicated by the
presence of both ICD-9-CM codes for fever and neu-
tropenia. It is possible that this was an underestimation
of patients with FN if some patients who present with
fever and neutropenia are only discharged with the
diagnosis of neutropenia. In addition, viral infection
and upper respiratory infection are separate ICD-9-CM
codes, but likely represent a spectrum of overlapping
diseases that cannot be fully differentiated using this
database. Variation in administrative coding and clinical
management may exist between regions in the US. Im-
portantly, administrative databases do not hold detailed
information regarding the patients’ cancer staging, therapy
regimens, vital signs or laboratory values, which are all
important factors in the decision making regarding
admission for a patient experiencing FN [15, 24].
Conclusion
Our study demonstrates the substantial impact on
healthcare utilization by pediatric cancer patients with
Mueller et al. BMC Cancer  (2015) 15:388 Page 7 of 8discharges for FN, in a nationally representative dataset.
Previous studies have attempted to determine the feasibility
and safety of alternative approaches to clinical management
of pediatric FN, yet these practices have not been
widely accepted or adopted. Identification of the burden
of FN is a key step in the process of developing awareness
and motivation for a multi-center or national study to im-
prove care of pediatric cancer patients experiencing FN.
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